Siponimod (Mayzent®). HTA ID: 19053

Assessment Status Assessment Process Complete
HTA ID 19053
Drug Siponimod
Brand Mayzent®
Indication For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Assessment Process
Rapid review commissioned 03/12/2019
Rapid review completed 13/01/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of siponimod compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/01/2020
Pre-submission consultation with Applicant 02/03/2020
Full submission received from Applicant 20/05/2020
Preliminary review sent to Applicant 17/09/2020
NCPE assessment re-commenced 15/10/2020
Factual accuracy sent to Applicant 04/01/2021
NCPE assessment re-commenced 08/01/2021
NCPE assessment completed 25/02/2021
NCPE assessment outcome The NCPE recommends that siponimod not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations December 2021.